Abstract
The penetration of TFLX into the paranasal sinus mucosa and tissue after single consecutive after-meal administrations was examined in patients with chronic sinusitis who had undergone a radical operation on the maxillary sinus for a nasal polypectomy. The following results were obtained:
1. Measurements were performed on 23 specimens consisting of 4 specimens from the group of patients receiving a single 150mg dose, 13 specimens from the the group receiving a single 300mg dose and 6 specimens from the groups receiving 600mg/day in 2 divided doses for from 3 to 7 consecutive days.
2. The TFLX concentrations in the maxillary sinus mucosa and nasal polyp tissue were 0.40 to 0.72 (mean 0.54) μg/g in the patients receiving a single 150mg dose, <0.01 to 2.51 (mean 0.73) μg/g in those receiving a single 300mg dose and 0.18 to 3.24 (mean 1.47) μg/g in those receiving a consecutive administration of 600mg/day in 2 divided doses. The ratios of these levels to the blood concentrations were 1.04, 1.00 and 1.27, respectively, indicating a high tissue penetration.
Based on the above findings, TFLX appears to be a promising drug whcih may have an excellent clinical effect on otorhinolaryngological infections when administered in a consecutive after-meal regimen.
